Importantly, anti-tumor effects without adverse effects were achieved in CTLA-4 heterozygous mice, while both anti-tumor and adverse effects were observed only in homozygous mice, indicating distinct genetic requirement for the adverse effects and anti-tumor efficacy. The gene discussed is CTLA4; the disease is neoplasm.